
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Rheumatoid Arthritis Therapeutics Market**

According to Intelli, the U.S. Rheumatoid Arthritis Therapeutics Market size was valued at USD 16,428.05 Million in 2024 and is projected to reach USD 23,398.13 Million by 2032, growing at a CAGR of 4.94%% from 2025 to 2032.



Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disorder that primarily targets the joints, causing inflammation, pain, stiffness, and eventual joint damage. Unlike osteoarthritis, RA occurs when the immune system mistakenly attacks healthy joint tissues. Over time, this can cause joint deformity and loss of function. Common signs and symptoms of RA include joint pain, swelling, redness, and warmth around the joints. It typically affects smaller joints first, such as those in the hands and feet, and often occurs symmetrically. Other symptoms may include fatigue, low-grade fever, and weight loss. The exact cause of RA is unknown, but several risk factors contribute to its development. These include genetics, gender (more common in women), age, smoking, obesity, and certain environmental exposures. Early recognition and treatment are crucial to managing symptoms and preventing long-term joint damage. Fortunately, advancements in medical science have transformed the landscape of RA treatment. Patients now have access to a diverse range of therapies, including traditional disease-modifying antirheumatic drugs (DMARDs), advanced biologic agents, and Janus kinase (JAK) inhibitors. These treatments help reduce symptoms, control inflammation, slow the progression of joint damage, and enhance overall quality of life.

**U.S. Rheumatoid Arthritis Therapeutics Market Definition**

**​**The U.S. Rheumatoid Arthritis Therapeutics Market encompasses the development, approval, and commercialization of pharmaceutical treatments aimed at managing RA. This market includes a range of therapeutic options such as DMARDs, biologic agents, JAK inhibitors, and emerging biosimilars. It also covers various distribution channels, including hospital pharmacies, retail outlets, and online platforms.

**U.S. Rheumatoid Arthritis Therapeutics Market Overview**

**​**The U.S. Rheumatoid Arthritis Therapeutics market is experiencing robust growth, driven by several key factors. The increasing prevalence of RA, particularly among the aging population, has expanded the patient base requiring effective treatment options. Advancements in biologic therapies and the introduction of biosimilars have significantly impacted the treatment landscape for Rheumatoid Arthritis (RA), enhancing both efficacy A close-up of hands holding a tablet and a pen

Description automatically generatedand accessibility, which in turn drives market growth. Biologic therapies are advanced drugs derived from living organisms that target specific components of the immune system involved in RA, such as tumor necrosis factor (TNF), interleukins, or B and T cells. These targeted treatments offer greater precision and effectiveness in reducing inflammation, slowing disease progression, and improving joint function compared to traditional medications. Biosimilars, on the other hand, are nearly identical copies of original biologic drugs whose patents have expired. While offering the same therapeutic benefits, biosimilars are typically more affordable. Their entry into the market has increased competition, lowered treatment costs, and improved access for a broader patient population. Significant investments in research and development have led to the discovery of novel therapeutics, further propelling market growth. Collectively, these factors are shaping a dynamic and expanding RA therapeutics market in the United States.

**U.S. Rheumatoid Arthritis Therapeutics Market Segmentation**

The U.S. Rheumatoid Arthritis Therapeutics Market is segmented based on several key factors, allowing for a more detailed understanding of trends, demands, and targeted treatment strategies.

**U.S. Rheumatoid Arthritis Therapeutics Market, By Drug Class**

* **Conventional DMARDs**
* **Biologic DMARDs**
* **JAK Inhibitors**
* **NSAIDs and Corticosteroids**

**​**The U.S. Rheumatoid Arthritis therapeutics market is segmented by drug class into Conventional DMARDs, Biologic DMARDs, JAK Inhibitors, and NSAIDs and Corticosteroids. Biologic DMARDs, including agents like adalimumab and etanercept dominate the market. Conventional DMARDs, such as methotrexate, remain foundational in RA treatment, especially in early disease stages or in combination therapies. JAK Inhibitors, like tofacitinib and baricitinib, have gained traction due to their oral administration and comparable efficacy to biologics, offering an alternative for patients seeking non-injectable options. NSAIDs and corticosteroids continue to play a role in symptom management, providing relief from pain and inflammation, though they do not alter disease progression.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Rheumatoid Arthritis Therapeutics Market, By Route of Administration**

* **Oral**
* **Injectable**
* **Infusion**

**​**The U.S. Rheumatoid Arthritis therapeutics market is segmented by route of administration into oral, injectable, and infusion therapies, each playing a distinct role in patient management. Oral medications, such as conventional DMARDs like methotrexate and NSAIDs, are popular due to their convenience and ease of use, which enhances patient adherence to treatment. As a result, they are often the first choice for many individuals with RA. On the other hand, injectable therapies, especially biologic agents like adalimumab and etanercept, have become increasingly favored for their precise targeting of immune mechanisms, making them particularly effective in managing moderate to severe cases of RA and providing superior disease control. Infusion treatments, like infliximab, are typically administered in clinical settings and are reserved for patients requiring intensive therapy. The choice of administration route is influenced by factors such as disease severity, patient preference, and treatment response, underscoring the importance of personalized therapeutic approaches in RA management.

**U.S. Rheumatoid Arthritis Therapeutics Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

In the U.S. rheumatoid arthritis therapeutics market, hospital pharmacies hold the largest market share. This dominance is largely due to their close proximity to healthcare settings, ensuring quick access to medications after diagnosis or prescription modifications. Hospital pharmacies are well-equipped to manage complex treatment protocols, including the administration of biologics and infusion therapies, and provide continuous service to meet urgent patient needs. Retail pharmacies, encompassing both chain and independent outlets, provide convenient access to a range of medications, including conventional DMARDs and NSAIDs, contributing to their significant role in the distribution network. Online pharmacies have gained traction, particularly during the COVID-19 pandemic, by A close-up of hands holding a tablet and a pen

Description automatically generatedoffering the convenience of home delivery and expanding access to medications, though they currently represent a smaller segment of the market.

**Key Players**

The “U.S. rheumatoid arthritis therapeutics market " study report will provide valuable insight emphasizing the U.S. market. The major players in the market AbbVie Inc., Amgen Inc., Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb, Roche Holding AG, Eli Lilly and Company, Novartis, GlaxoSmithKline, AstraZeneca, Sanofi, Horizon Therapeutics, Teva Pharmaceutical Industries Ltd., BioMarin Pharmaceutical, Otsuka Pharmaceutical Co., Ltd. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, the U.S. FDA approved TYENNE®, (tocilizumab-aazg), a biosimilar referencing Actemra® (tocilizumab), developed by Fresenius Kabi. The approval of TYENNE® represents Fresenius Kabi’s third FDA-approved biosimilar in the U.S., highlighting the company’s dedication to enhancing its portfolio of immunology and oncology biosimilars.
* In 2024, SetPoint Medical is leading the way in RA treatment with its RESET-RA clinical study, which tests the SetPoint System, a neuroimmune modulation device. This innovative device uses vagus nerve stimulation to trigger the body's natural anti-inflammatory responses, providing a promising alternative for patients with moderate-to-severe RA who have not had sufficient results from, or cannot tolerate, biologic or targeted synthetic DMARDs.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. rheumatoid arthritis therapeutics market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a A close-up of hands holding a tablet and a pen

Description automatically generatedplayer's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. rheumatoid arthritis therapeutics market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET, BY DRUG CLASS**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Conventional DMARDs

5.3 Biologic DMARDs

5.4 JAK Inhibitors

5.5 NSAIDs and Corticosteroids

**6 U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET, BY** **ROUTE OF ADMINISTRATION**

6.1 Overview

6.2 Oral

6.3 Injectable

6.4 Infusion

**7 U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

7.1 Overview

7.2 Hospital Pharmacies

7.3 Retail Pharmacies

7.4 Online Pharmacies

1. **U.S. RHEUMATOID ARTHRITIS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

A close-up of hands holding a tablet and a pen

Description automatically generated**9.1 AbbVie Inc.**

* + 1. Overview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. A close-up of hands holding a tablet and a pen

     Description automatically generated **Roche Holding AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Eli Lilly and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Novartis**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **GlaxoSmithKline**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. A close-up of hands holding a tablet and a pen

     Description automatically generated**Sanofi**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Horizon Therapeutics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Teva Pharmaceutical Industries Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **BioMarin Pharmaceutical**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Otsuka Pharmaceutical Co., Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. A close-up of hands holding a tablet and a pen

   Description automatically generated**KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research